BPMC - Blueprint Medicines Corporation Stock Trading

Blueprint Medicines Reports Second Quarter 2021 Financial Results -- Obtained FDA approval and launched AYVAKIT™ (avapritinib) for advanced systemic mastocytosis -- -- Expect topline data from Part 2 of registration-enabling Phase 2 PIONEER trial of AYVAKIT in non-adv...

MD Anderson and Blueprint Medicines Announce Strategic Collaboration to Accelerate BLU-222 Development Translational research will focus on advancing therapeutic strategies for Blueprint Medicines' potent and selective CDK2 inhibitor across a broad range of tumor types PR Ne...

Blueprint Medicines to Report Second Quarter 2021 Financial Results on Thursday, July 29, 2021 PR Newswire CAMBRIDGE, Mass. , July 22, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), today announced that it will host a live conference ca...